Establishment of R&D Complex in Baegot District, Siheung
Expansion of Global New Drug Pipeline
Support for Mid- to Long-Term Investment

Woori Bank will provide financial support of 1 trillion won over the next five years to Chong Kun Dang Pharmaceutical Corp. for new drug research and development (R&D) and the expansion of its global production bases. The plan is to expand productive finance for advanced strategic industries by establishing a credit line that preemptively reflects the large-scale investment demand of the bio industry.

(Photo right) Jinwan Jung, President of Woori Bank, and (left) Youngjoo Kim, CEO of Chong Kun Dang, are posing for a commemorative photo after signing a business agreement at Woori Bank headquarters on the 26th. Courtesy of Woori Bank.

(Photo right) Jinwan Jung, President of Woori Bank, and (left) Youngjoo Kim, CEO of Chong Kun Dang, are posing for a commemorative photo after signing a business agreement at Woori Bank headquarters on the 26th. Courtesy of Woori Bank.

View original image

On May 26, Woori Bank announced that it had signed a financial support agreement with Chong Kun Dang Pharmaceutical Corp. at its headquarters in Jung-gu, Seoul, to strengthen the competitiveness of the advanced bio industry. The signing ceremony was attended by Jinwan Jung, CEO of Woori Bank, Youngjoo Kim, CEO of Chong Kun Dang Pharmaceutical Corp., and other key executives from both companies. Through this agreement, the two sides have established a total financial support limit of 1 trillion won for the next five years and agreed to build a mid- to long-term cooperation system. Woori Bank plans to support Chong Kun Dang’s investment plans, including new drug development and R&D investment, the establishment of research and production infrastructure, trade and overseas business financing, and mutually beneficial finance for partner companies.


Chong Kun Dang is pushing forward with the establishment of an advanced biopharmaceutical complex R&D cluster in the Baegot district of Siheung, Gyeonggi Province, to strengthen its global competitiveness. At the same time, the company is expanding its global new drug pipeline and reinforcing its overseas research and business bases, thereby broadening its foundation for future growth.


A key feature of this agreement is that the credit line was set in advance to reflect Chong Kun Dang’s future investment needs. This is expected to enhance the speed, stability, and predictability of funding execution, reduce burdens arising from changes in the financial environment, and enable the company to focus on long-term R&D and global business expansion.



Jinwan Jung, CEO of Woori Bank, stated, “Chong Kun Dang is a leading Korean bio company that is enhancing its R&D capabilities and global competitiveness around the Baegot R&D cluster. Through this agreement, Woori Bank will faithfully fulfill its financial role to ensure that Chong Kun Dang’s R&D and global ambitions bear fruit, and we will stand as a strong partner in the industry’s growth.” Woori Bank plans to continue expanding productive finance that connects advanced strategic industries and real-economy investment, supporting the strengthening of national industrial competitiveness and laying the foundation for future growth.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing